Regeneron Hopes Its High-Dose Aflibercept Will Ease Eylea Pressure

The anticipated approval of Regeneron Pharmaceuticals, Inc.’s high-dose formulation of aflibercept may help offset some of the pressure on Eylea (aflibercept) as the drug maker’s first quarter 2023 earnings show the drug’s sales coming in below expectations for the second quarter in a row. Meanwhile, executives expressed excitement about an upcoming presentation of data for the company’s bispecific antibody for multiple myeloma, another addition to its portfolio in a competitive space.

Regeneron announced its Q1 earnings on 4 May, reporting total revenues of $3.2bn, up 7% from $3bn in the first quarter of 2022, but Eylea saw its sales fall by 6%, to $1.4bn, which the Tarrytown, NY-based company attributed primarily to an increase in sales-related deductions, partly offset by higher sales volume